Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors
Clinical trial NCT07272590 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07272590
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-30
- Primary completion
- 2027-06-01
- Enrollment
- 290
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.